Issues related to pharmaceutical manufacturing, drug pricing, and orphan drugs. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
2026 · 3rd Quarter (July 1 - Sep 30)
BRIDGEBIO PHARMA
Filed by MARSHALL & POPP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- MARSHALL & POPP, LLC
- Client
- BRIDGEBIO PHARMA
- Filing UUID
- 5521b317-2bfb-4acf-ab03-3ff94ba6e9f6
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.